HIV

World AIDS day highlights awareness gaps

World AIDS day highlights awareness gaps

By

The number of new HIV cases has held steady since the 1990s. Researchers note it is progress of a sort, but that driving numbers down requires one basic step: testing, testing, testing.

Cigna lowers price of some HIV medications

The deal will cap the monthly price some patients may pay for medications such as Atripla.

Five things for pharma marketers to know: Monday, August 25

Five things for pharma marketers to know: Monday, August 25

By

Roche backs away from Chugai but embraces InterMune, Merck rumored on track to score first PD-1 approval, a new Ebola strain may have surfaced and JNJ scoops up experimental anti-TNF.

Merck adds heat to HCV competition

Merck adds heat to HCV competition

By

Phase-II data show reduced hepatitis-C RNA levels among HIV-positive patients, the drugmaker shared at a medical meeting. Boehringer also released co-infection data.

EMA approves ViiV's Tivicay

The GlaxoSmithKline-Pfizer-Shionogi joint venture scored an FDA approval in August.

HIV/AIDS site makes healthcare reform personal

HIV/AIDS site makes healthcare reform personal

By

The Kaiser Family Foundation's just-launched website, funded by Gilead, addresses healthcare reform from a distinct perspective.

Suddenly hot ViiV sends HIV cocktail to FDA

Suddenly hot ViiV sends HIV cocktail to FDA

By

Adding Epzicom to Tivicay in a once-daily cocktail could further boost GSK's HIV franchise, and possibly chip away at Atripla's dominance.

Business briefs: Gilead, Boehringer, Rx sample ban

Gilead's Striblid faces hurdle in Germany, Boehringer and Roche team up for companion diagnostic effort and Wisconsin hospital system says no to samples

Business briefs: CDC, Facebook, Shire

CDC finds that non-Medicare adults make up the majority of preventable heart attack and stroke cases; a Facebook study shows groups can influence HIV screening; and a Shire ADHD drug gets a "no" from Germany

New daily HIV med could put Atripla on the defensive

New daily HIV med could put Atripla on the defensive

By

The GSK-Pfizer-Shionogi daily HIV medication gets the regulatory all-clear. The approval could put BMS/Gilead's best-selling daily med Atripla on the defensive.

Business briefs: Gilead, Bristol-Myers Squibb and GlaxoSmithKline

A two-year study shows Gilead's Quad pill outpaces an older combination drug over two years, and GSK is seeking to expand its oncology presence.

HIV messaging goes communal

HIV messaging goes communal

By

Messaging around HIV testing now mixes individual concerns with community protection. Recent efforts, like those of the CDC and Greater than AIDS, try to make getting tested an empowering act.

Business briefs: Pharma's ad spend, Baby sheds HIV status

Pharma pared back its ad spend in 2012, a baby born HIV-positive is virus-free two-and-a-half years later, and Boston Children's Hospital is making its own apps.


Does a health psychology approach hold the key to Rx adherence? In MM&M's latest Leadership Exchange Uncut eBook, industry stakeholders from the payer, provider, academic and pharma realms explore the "why" behind medicine taking. Access here.

Email Newsletters